Antiphospholipid syndrome and anticoagulation quality: A clinical challenge

Atherosclerosis

Volumn 244, Issue , 2016, Pages 48-50

  Pastori, Daniele ^a   Parrotto, Sandro ^a   Vicario, Tommasa ^a   Saliola, Mirella ^a   Mezzaroma, Ivano ^a   Violi, Francesco ^a   Pignatelli, Pasquale ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Antiphospholipid syndrome; Time in therapeutic range; Warfarin

Indexed keywords

ACENOCOUMAROL; AMIODARONE; ANTIVITAMIN K; AZATHIOPRINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYCHLOROQUINE; MYCOPHENOLATE MOFETIL; WARFARIN; ANTICOAGULANT AGENT; VITAMIN K GROUP;

ADULT; ANTICOAGULATION; ANTIPHOSPHOLIPID SYNDROME; ARTERY THROMBOSIS; ARTICLE; ATRIAL FIBRILLATION; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; CLINICAL ARTICLE; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; KIDNEY FUNCTION; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; ANTAGONISTS AND INHIBITORS; BLOOD; BLOOD CLOTTING; COMPLICATION; DRUG EFFECTS; HEALTH CARE QUALITY; MIDDLE AGED; RECURRENT DISEASE; THROMBOSIS; TREATMENT OUTCOME;

ANTICOAGULANTS; ANTIPHOSPHOLIPID SYNDROME; BLOOD COAGULATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; QUALITY OF HEALTH CARE; RECURRENCE; THROMBOSIS; TREATMENT OUTCOME; VITAMIN K;

EID: 84946887713     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2015.10.105     Document Type: Article

References (19)

1. Giannakopoulos B., Krilis S.A. The pathogenesis of the antiphospholipid syndrome. N. Engl. J. Med. 2013, 368:1033-1044.
2. Lim W., Crowther M.A., Eikelboom J.W. Management of antiphospholipid antibody syndrome: a systematic review. JAMA J. Am. Med. Assoc. 2006, 295:1050-1057.
3. Holbrook A., Schulman S., Witt D.M., et al. Evidence-based management of anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012, 141:e152S-e184S.
4. Finazzi G., Marchioli R., Brancaccio V., et al. A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J. Thromb. Haemost. JTH 2005, 3:848-853.
5. Crowther M.A., Ginsberg J.S., Julian J., et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N. Engl. J. Med. 2003, 349:1133-1138.
6. Cervera R., Serrano R., Pons-Estel G.J., et al. Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients. Ann. Rheum. Dis. 2015 Jun, 74(6):1011-1018.
7. Hylek E.M. Vitamin K antagonists and time in the therapeutic range: implications, challenges, and strategies for improvement. J. Thromb. Thrombolysis 2013, 35:333-335.
8. White H.D., Gruber M., Feyzi J., et al. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. Arch. Intern. Med. 2007, 167:239-245.
9. Pastori D., Pignatelli P., Saliola M., et al. Inadequate anticoagulation by vitamin K antagonists is associated with major adverse cardiovascular events in patients with atrial fibrillation. Int. J. Cardiol. 2015, 201:513-516.
10. Miyakis S., Lockshin M.D., Atsumi T., et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J. Thromb. Haemost. JTH 2006, 4:295-306.
11. January C.T., Wann L.S., Alpert J.S., et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation 2014, 130:e199-267.
12. Rosendaal F.R., Cannegieter S.C., van der Meer F.J., et al. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb. Haemost. 1993, 69:236-239.
13. Ciccone M.M., Cortese F., Corbo F., et al. Bemiparin, an effective and safe low molecular weight heparin: a review. Vasc. Pharmacol. 2014, 62:32-37.
14. Ames P.R., Margaglione M., Ciampa A., et al. Increased warfarin consumption and residual fibrin turnover in thrombotic patients with primary antiphospholipid syndrome. Thromb. Res. 2011, 127:595-599.
15. Khamashta M.A., Cuadrado M.J., Mujic F., et al. The management of thrombosis in the antiphospholipid-antibody syndrome. N. Engl. J. Med. 1995, 332:993-997.
16. Kenet G., Lutkhoff L.K., Albisetti M., et al. Impact of thrombophilia on risk of arterial ischemic stroke or cerebral sinovenous thrombosis in neonates and children: a systematic review and meta-analysis of observational studies. Circulation 2010, 121:1838-1847.
17. Wallentin L., Yusuf S., Ezekowitz M.D., et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 2010, 376:975-983.
18. Wallentin L., Lopes R.D., Hanna M., et al. Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation. Circulation 2013, 127:2166-2176.
19. Piccini J.P., Hellkamp A.S., Lokhnygina Y., et al. Relationship between time in therapeutic range and comparative treatment effect of rivaroxaban and warfarin: results from the ROCKET AF trial. J. Am. Heart Assoc. 2014, 3:e000521.